In GCT, reduced Oct-4 expression has been described in cisplatin resistance [31], and Gutekunst et al. could show that in GCTs Oct-4–dependent high constitutive Noxa levels are required for cisplatin hypersensitivity [32]. The gene discussed is POU5F1; the disease is granular cell tumor.